Plain-English translation of NCT05963698 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Atrial Fibrillation research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
LAAOS-4 is testing a device called the WATCHMAN, which is a small implant placed inside the heart to block off a part called the left atrial appendage. This pouch-like area is where blood clots often form in people with atrial fibrillation. The trial is studying whether this device can help prevent strokes and blood clots in people whose hearts are already treated with blood-thinning medications.
People with atrial fibrillation face a high risk of stroke even when taking blood thinners. Researchers want to know if this implant device can provide extra protection by physically blocking the area where dangerous clots form, offering patients another way to stay safe.
You likely qualify if…
You likely don't qualify if…
If you are randomly assigned to receive the WATCHMAN device, you will undergo a minimally invasive procedure where doctors guide the implant through a catheter into your heart—you'll typically go home the same day or after a short hospital stay. If you are assigned to standard care, you will continue your current blood thinner medication and regular medical check-ups. Either way, you will have follow-up visits to monitor your health and watch for any signs of stroke or complications over the expected duration of the trial.
AI-generated summary from trial data · Jul 10, 2026 · Not medical advice
United States